Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Decline in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 500 shares, a drop of 97.1% from the February 28th total of 17,500 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 365,200 shares, the days-to-cover ratio is presently 0.0 days.

Provectus Biopharmaceuticals Stock Performance

OTCMKTS:PVCT traded down $0.01 during trading hours on Thursday, hitting $0.09. The company had a trading volume of 24,873 shares, compared to its average volume of 237,861. The stock has a 50-day moving average price of $0.11 and a 200 day moving average price of $0.11. Provectus Biopharmaceuticals has a 52 week low of $0.04 and a 52 week high of $0.21.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.